$RMD

ASX healthcare stocks, led by CSL (ASX:CSL) and ResMed (ASX:RMD), gained institutional investor interest, with Morgan Stanley noting increased overweight positions. RBC Capital upgraded several healthcare stocks, citing better-than-expected earnings. Healius (ASX:HLS) plans to sell Agilex for $160M to Novotech, addressing balance sheet challenges. Paradigm Biopharmaceuticals (ASX:PAR) delayed its trading resumption to address financial matters.

ResMed Inc. (RMD) reported a 9% revenue increase to $1.5B in Q4 2026, driven by strong demand for sleep devices. RBC Capital upgraded RMD to Outperform, raising its price target to $262. However, the company faces risks from competition, lower-than-expected 2027 guidance, and a ventilator recall. Hedge funds maintained interest, with some increasing stakes.

Analysts rate ResMed (RMD) stock as 'Moderate Buy' with price targets up to $320, suggesting 40% upside from current levels, according to Barchart.

RBC Capital Markets upgraded five ASX-listed healthcare stocks to outperform, citing positive earnings growth and attractive valuations. CSL (ASX: CSL) was highlighted for market share gains, with a $213 price target. ResMed (ASX: RMD) was noted for capital management, with a $262 target. Ramsay Healthcare (ASX: RHC) was praised for cost control, with a $68 target. Fisher & Paykel (ASX: FPH) showed strong growth, with a $52 target. Nanosonics (ASX: NAN) had mixed results but a $3.75 target.

ResMed Inc. (RMD), a $31.5B medical device company, trades 23.4% below its 52-week high. Its Q4 2026 revenue rose 8.6% YoY, meeting estimates, while adjusted EPS beat forecasts at $2.95. However, operating margin declined to 30.7% from 33.7% due to higher costs. RMD's stock has fallen 20.5% over the past year, underperforming the healthcare sector ETF XLV. Analysts have a 'Moderate Buy' consensus with a mean price target of $238.20, implying 9.1% upside.

ResMed Inc (RMD) shares rose 3% after RBC Capital upgraded it to Outperform, raising the price target to $262. The upgrade cited ResMed's leadership in sleep apnea devices, strong Q4 growth, and FDA recall of a competitor's device. RBC expects high single-digit EPS growth over three years.

AI regulation odds fell to 17% after Trump called concerns a 'hoax'. Dave & Buster's (PLAY) reported a Q2 loss. Enova (ENVA) dropped after withdrawing regulatory applications. ResMed (RMD) rose on an RBC upgrade. Apple's (AAPL) 'Widow's Bay' won 14 Emmys.

Analysts made several calls on Tuesday, including upgrades for Nokia (NOK), The New York Times (NYT), Agilon (AGL), and Eli Lilly (LLY). Price targets were raised for NYT ($82), AGL ($125), and Palantir (PLTR, $250). Other notable actions include initiations on Janus Living, Vishay Intertechnology (VSH), and Samsara (IOT).

Wall Street analysts issued research calls on several companies. Eli Lilly (LLY) was upgraded to Buy with a $1,400 target, Etsy (ETSY) to Outperform with a $525 target, and New York Times (NYT) to Buy with an $82 target. Downgrades included Aptiv (APTV) to Neutral with a $56 target, Lear (LEA) to Neutral with a $150 target, and Magna (MGA) to Neutral with a $72 target. New initiations included Autodesk (ADSK) with a Neutral rating and $215 target, Rivian (RIVN) with a Neutral rating and $18 targ

Analysts updated recommendations for several companies. Baptista Research raised Abercrombie & Fitch's price target to $163.40 but downgraded it to hold. Eli Lilly was upgraded to buy by Berenberg, which also raised its target to $1,400. Other companies affected include Coinbase, Ulta Beauty, and Philip Morris.